ARTICLE | Finance
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
By Paul Bonanos, Director of Biopharma Intelligence
November 8, 2024 11:12 PM UTC
The U.S. election likely quieted most biotechs’ financial news this week, but a handful of companies still raised funds to support ongoing clinical and preclinical work.
Ahead of a presentation of data from its gene therapy for Rett syndrome, Neurogene Inc. (NASDAQ:NGNE) said Monday that a syndicate is providing $200 million in a PIPE deal to support further development. The biotech is preparing a registrational trial of the therapy, which uses an adeno-associated virus to deliver the MECP2 gene…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654135/neurogene-draws-200m-pipe-ahead-of-next-week-s-rett-syndrome-data